Longboard Pharmaceuticals, Inc. Overview
Pro stress-test →Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company was acquired by H. Lundbeck A/S on December 2, 2024, and is now a wholly owned subsidiary of Lundbeck.
Strategic Profile
Pro stress-test →Longboard was founded in 2020 based on assets spun out from Arena Pharmaceuticals after it was acquired for $6.7 billion by Pfizer. Lundbeck finalized acquisition in December 2024 for $2.6 billion; the company had about 50 full-time employees at the time and believes Longboard's lead asset has potential to become a blockbuster product helping treat patients with Dravet syndrome and Lennox-Gastaut syndrome among other rare epilepsies.
Competitive Landscape
Pro stress-test →Longboard addresses developmental and epileptic encephalopathies including Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex, and CDKL5 deficiency disorder. The rare epilepsy space features competitors including GW Pharmaceuticals (acquired, now Jazz Pharmaceuticals), Zogenix, Marinus Pharmaceuticals, and other specialty epilepsy developers. Longboard's GPCR-selective approach and first-mover status with bexicaserin provide differentiation in a high-unmet-need market.
Industry Context
Longboard Pharmaceuticals, Inc. operates in Rare neurological disease therapeutics.
Key facts
Founded: 2020 · Headquarters: San Diego, US · Employees: ~50